Surface Oncology

Surface Oncology is an immuno-oncology company on a mission to break through and deliver transformative outcomes for people with cancer. Surface uses multiple established platforms to characterize new therapeutic antibody candidates which are designed to activate both innate and adaptive immunity to dramatically improve and lengthen patient responses to cancer immunotherapy. The company has a pipeline of novel immunotherapies and a strategic collaboration with Novartis.

Headquarters Cambridge, MA
Pipeline Phase 1
Twitter @surfaceoncology
Partners Novartis